Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689052 · ClinicalTrials.gov registry record · Phase 2
Pramipexole ER vs. Placebo in Fibromyalgia
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00689052 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 61 participants.
The verdict
NCT00689052, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia. The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.
Interventions
- DRUG placebo
- DRUG pramipexole ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00689052
The ClinicalTrials.gov registry entry for NCT00689052 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00689052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00689052 about?
NCT00689052 is a clinical study titled "Pramipexole ER vs. Placebo in Fibromyalgia". The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia. The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extende...
What is the current status of trial NCT00689052?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2008-07.
What interventions are being tested in trial NCT00689052?
The interventions under investigation include: placebo (DRUG), pramipexole ER (DRUG).
Who is sponsoring clinical trial NCT00689052?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.